{"nctId":"NCT01294462","briefTitle":"Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)","startDateStruct":{"date":"2011-02"},"conditions":["Acute Coronary Syndrome","Percutaneous Coronary Intervention"],"count":801,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Ticagrelor","Drug: Acetylsalicylic acid ASA"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clopidogrel","Drug: Acetylsalicylic acid ASA"]}],"interventions":[{"name":"Ticagrelor","otherNames":["AZD6140"]},{"name":"Clopidogrel","otherNames":["Plavix"]},{"name":"Acetylsalicylic acid ASA","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of signed informed consent\n* Index event of non-ST or ST segment elevation ACS\n\nExclusion Criteria:\n\n* Index event is an acute complication of percutaneous coronary intervention\n* Patient has undergone Percutaneous Coronary Intervention (PCI) after the index event before the first dose of study treatment\n* Oral anticoagulation therapy that cannot be stopped\n* The conditions associated with increased risk of bradycardiac events","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Major Bleeding","description":"Time to first occurrence of any major bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Major Adverse Cardiac Events (MACE)","description":"Time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Major and Minor Bleeding","description":"Time to first occurrence of any major or minor bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"16.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite of All-cause Mortality, MI or Stroke","description":"Time to first occurrence of any event from the composite of death from any causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":92,"n":387},"commonTop":["Constipation","Nasopharyngitis","Pyrexia","Insomnia","Back pain"]}}}